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Abstract 
Background: The three members of the ring‑infected erythrocyte surface antigen (RESA) proteins family share high 
sequence homologies, which impair the detection and assignment to one or another protein of some pathogenic 
processes inherent to Plasmodium falciparum malaria. The present study was intended to determine if the antibody 
and inflammatory responses of children living in a malaria‑endemic area varied depending on the RESA‑1, RESA‑2 
or RESA‑3 proteins and the severity of the disease, two groups of severe and uncomplicated malaria cases being 
considered.
Methods: Two synthetic peptides representing predicted B cell epitopes were designed per RESA protein, all located 
outside of the 3′ and 5′ repetition blocks, in order to allow an antibody detection specific of each member of the fam‑
ily. Recombinant rRESA‑1B and rRESA‑3B proteins were also engineered. Two groups of Beninese children admitted to 
hospital in 2009 for either uncomplicated or severe malaria were compared for their plasma levels of IgG specifically 
recognizing each recombinant RESA protein or synthetic peptide, and for their plasma inflammatory cytokine levels 
(IFN‑γ, TNF‑α and IL‑10), taking into account host and parasite genetic factors.
Results: The absence of IgG cross‑reactivity between rRESA proteins and their protein carrier as well as between 
each RESA peptide and a non‑epitopic RESA control peptide validated the use of the engineered recombinant pro‑
teins and peptides for the measurement of plasma IgG. Taking into account age, fever duration and parasitaemia, a 
multiple logistic regression performed on children clustered according to their antibody responses’ profiles concluded 
to an increased risk of severe malaria for P2 (representative of RESA‑1) responders (P = 0.007). Increased IL‑10 plasma 
levels were found in children harbouring multiclonal P. falciparum infections on the basis of the T1526G resa2 gene 
polymorphism (P = 0.004).
Conclusions: This study provided novel tools to dissect the seroreactivity against the three members of the RESA 
protein family and to describe its relation to protection against malaria. It suggested the measurement of plasma 
antibodies raised against specific peptides to serve as predictive immunologic markers for disease severity. Lastly, it 
reinforced previous observations linking the T1526G resa2 gene mutation to severe malaria.
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Background
Although estimated incidence rates of malaria have 
declined by 30% globally between 2000 and 2013, and 
mortality rates by 47%, malaria is still the most wide-
spread of all human infectious diseases, responsible for 
an estimated 5,84,000 deaths in 2013 [1]. Despite the 
observation of the largest absolute decreases in deaths 
in Africa, the disease still affects especially this continent 
and particularly sub-Saharan Africa.
Plasmodium falciparum is the most prevalent (80% of 
all infections) and lethal (90% of deaths occurring) of the 
malaria parasites infecting humans. Malaria pathogenesis 
is linked to the erythrocytic cycle of the parasite. Immedi-
ately after the red cell invasion by the parasite, trafficking 
of hundreds of P. falciparum proteins to the erythrocyte 
cytoplasm and membrane gives rise to a progressive 
mechanical, functional and antigenic remodelling of the 
host cell in order to create an adequate environment and 
to overcome host responses. One such protein, called 
Pf155/RESA (ring-infected erythrocyte surface antigen, 
RESA-1), stored within dense granules in the invasive 
merozoites, is released in the parasitophorous vacuole 
upon invasion and exported to the erythrocyte mem-
brane very shortly after invasion [2], where it interacts 
with the erythrocyte cytoskeleton protein spectrin [3], 
stabilizing the infected red blood cell cytoskeleton [4] 
and conferring increased erythrocyte membrane rigidity 
upon febrile exposure [5–7]. RESA-1 is the best-known 
protein of a small protein family encoded by three highly 
related genes (PFA0110W resa1; PF11_0511 resa2 and 
PF11_0509 resa3). RESA-1 and RESA-3 show a high 
sequence homology including a PEXEL motif known to 
be important for the appropriate trafficking of many Plas-
modium exported proteins [8]. Both RESA-1 and RESA-3 
have two repetitive domains (referred to as bloc 1 and 
bloc 2 repeat domains) and a domain with a high homol-
ogy to the human chaperone protein DnaJ [9]. Although 
slightly polymorphic, a peptide domain sharing homolo-
gies with the RESA-1 spectrin-binding domain is found 
on RESA-3. In contrast, RESA-2 does not contain these 
two repetitive domains nor display any homology with 
the spectrin-binding domain of RESA-1. The resa2 gene 
was initially described as a pseudogene [10] based on the 
presence of an internal stop codon, supposed to be dele-
terious, at position 1526. However, another study showed 
that resa2 is expressed in the parasite [11]. In some cases, 
the restoration of a complete protein, thanks to a muta-
tion, occurs and this non-truncated protein could be 
related to the physiopathology of severe malaria [12].
In this study, the main goal was to determine if 
the immune response of children living in a malaria-
endemic area varied depending on the protein (RESA-
1, RESA-2 or RESA-3) and the severity of the disease: 
uncomplicated malaria (UM) or severe malaria (SM). For 
this purpose, a transversal survey was conducted in the 
CNHU of Cotonou, Benin, among a population of 102 
children including 54 affected by SM and 48 by UM.
As previously done with the DBL6ε domain of 
VAR2CSA [13, 14], two peptides representing different 
predicted B cell epitopes from each RESA protein were 
used. Plasma immunoglobulin (Ig) G directed to peptides 
from RESA-1, -2 and -3 as well as RESA-1 and -3 recom-
binant proteins were evaluated by ELISA. RESA-1 has 
long been shown to be targeted by the adaptive immune 
response in populations living in endemic areas: anti-
bodies reacting with RESA-1 inhibit erythrocyte inva-
sion [15–18] and are associated with protection against 
clinical malaria [19–23]. The immunological response 
to RESA-2 and RESA-3 proteins is still unknown. Fur-
thermore, many serological studies used synthetic pep-
tides corresponding to C-terminal EENV repeats [16, 20, 
23–25] or non-repetitive RESA-1 peptides [17, 26, 27], 
all shared with RESA-3 and, therefore, making uncertain 
the true antigenic specificity of the immune response and 
its functional relevance. Plasma levels of pro-inflamma-
tory (TNF-α and IFN-γ) and anti-inflammatory (IL-10) 
cytokines known to be involved in both pathogenesis 
and defence mechanisms against malaria [28–32] were 
also measured. The red blood cell genetic polymorphisms 
resulting at the sixth amino acid position of the β chain 
of haemoglobin (Hb) in the replacement of a glutamic 
acid by a valine (HbS) or a lysine (HbC) are known to 
impact the immune response [33–36] and to be protec-
tive against malarial attacks [37–39]. Considering their 
importance in West Africa, [40, 41] their prevalence rates 
were determined in the population.
Except for RESA-1, the antigenic characteristics and 
functions of the RESA proteins family remain quite 
unknown. This study was an opportunity to continue 
the exploration of the different functions and implica-
tion of this proteins family. It allowed namely to dissect 
the immunological response (in terms of seroreactivity 
and plasma inflammatory cytokines) against RESA family 
during a plasmodial infection, according to disease sever-
ity. It also offered the opportunity to investigate the role 
of a recently described mutation occurring in the resa2 
gene.
Methods
Study population and sampling
At the arrival of the children in the paediatrics depart-
ment of the CNHU, gender, age, place of residence, anti-
malarial drug intake, and duration of symptoms prior 
to enrolment were documented by questionnaire. After 
clinical examination by a paediatrician, observations 
concerning the ongoing malarial attack were recorded. 
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Patients and samples were previously described [12]. 
Briefly, 102 children with symptomatic P.  falciparum 
malaria were recruited in the CNHU of Cotonou, Benin, 
from April to August 2009. They all lived in the urban 
area of Cotonou where malaria transmission is hetero-
geneous according to areas but perennial, with two sea-
sonal peaks corresponding to rainy seasons, from April 
to July and September to November [42]. The first group 
(n = 54) corresponded to children admitted to the Inten-
sive Care Unit for SM. All presented at least one of the 
symptoms defined by the World Health Organization as 
criteria for SM (severe anaemia, altered consciousness, 
convulsions, hypoglycaemia, acidosis, respiratory dis-
tress, and impaired visceral functions). The second group 
consisted of 48 outpatients with an UM attack. For each 
individual a 5  mL venous blood was collected in vacu-
tainers containing citrate phosphate dextrose adenine 
anticoagulant, before drug treatment administration. 
Plasmas were stored at −20°C for subsequent antibody 
testing. Infection with P.  falciparum was identified 
through the use of rapid diagnostic tests (Parascreen®, 
Zephyr Biomedical Systems, Goa, India) and peripheral 
parasitaemia by microscopy on Giemsa-stained blood 
smears. In addition, for each individual, two drops of 
fresh blood were collected onto filter paper for molecu-
lar studies. Negative control plasmas were obtained from 
18 healthy European adults who had not been exposed to 
malaria (Bichat-Claude Bernard Hospital, Paris, France). 
A pool of four plasmas from malaria immune Gabonese 
adult donors was used as a positive control.
The study was approved by the ethics committee of 
the Faculté des Sciences de la Santé of the University 
of Abomey-Calavi in Benin. For each child, a written 
informed consent from parents or legal guardians was 
obtained. The study was conducted in accordance with 
the Declaration of Helsinki.
Antigens
Synthetic peptides from RESA‑1, RESA‑2 and RESA‑3 proteins
RESA family proteins share high homology sequences. 
Protein sequence alignments were performed with RESA-1 
(accession number: PFA0110W/PF3D7_0102200), RESA-2 
(accession number: PF11_0512/PF3D7_1149500) and 
RESA-3 (accession number: PF11_0509/PF3D7_1149200) 
using the Geneious software 6.1.4. from Biomatters Ltd, 
by means of the integrated multiple sequence compari-
son by log-expectation (Muscle) algorithm and the default 
settings. RESA-1 and -2 (see Additional file 1) shared 38% 
(333 amino-acids) homology, RESA-1 and -3, 49.1% (535 
amino-acids) and RESA-2 and -3, 38.9% (361 amino-
acids). Thus, cross-reactive antibodies should exist, pre-
venting specific detection of the antigenic protein. To 
perform ELISA to evaluate the presence of RESA specific 
antibodies, six synthetic peptides that reproduced puta-
tive B cell epitopes of the RESA proteins were used. These 
peptides, whose sequences are shown in Table  1, were 
identified following B cell epitope predictions [43]. They 
were chosen to be located outside of the C-terminal and 
central repeats, which contain already known Pf155/RESA 
(RESA-1) epitopes [44], and to allow detection of protein 
specific antibodies. More precisely, they were chosen to be 
on a location where sequences are not conserved across 
the RESA proteins, leading to a given RESA protein-spe-
cific antibody detection. These peptides will be subse-
quently referred to as P1–P6, P1 and P2 being located on 
RESA-1, P3 and P4 on RESA-2, and P5 and P6 on RESA-3, 
as illustrated in Figure 1a. The peptides P1 (Figure 1b) and 
P2 (Figure  1c) shared 100% homology with RESA-1 and 
respectively, 11.1% (2 aa) and 26.7% (4 aa) homology with 
RESA-2, and 38.9% (7 aa) and 33.3% (5 aa) homology with 
RESA-3. The peptides P3 and P4 (Figure 1d), homologous 
to RESA-2, shared respectively 26.3% (5 aa) and 20% (3 aa) 
homology with both RESA-1 and -3. The peptides P5 (Fig-
ure 1b) homologous to RESA-3 shared no homology with 
RESA-1 or RESA-2 and P6 share 44.4% (4 aa) with RESA-1. 
A seventh peptide located on RESA-3 and not correspond-
ing to a B cell epitope was assigned as control peptide (P 
Ctl) for antibody measurement. P Ctl (Figure 1e) was 60, 
40 and 100% homologous to RESA-1 -2 and -3, respec-
tively. The peptides were synthesized with an N-terminal 
biotin group. They were solubilized and used at a final con-
centration of 0.3 µM.
Recombinant proteins from RESA‑1 and RESA‑3
Divergent central repetitive domains of RESA-1 and 
RESA-3 proteins were expressed as a carboxy-terminus 
fusion protein of the maltose binding protein (MBP) 
recombinant proteins will be referred to as rRESA-1B 
and rRESA-3B.
Central repetitive domains of RESA-1 (PlasmodB 
PFA0110W, bp 1428-1727) and RESA-3 (PlasmodB 
PF11_0509, bp 1407-1760) from the P.  falciparum FUP/
Table 1 Characteristics of  synthetic peptides from  the 
RESA proteins family
Antigens Sequence Residues Abbreviation
RESA‑1 Biotin‑KSSKSAKKLQQRTQANKQ‑
COOH
715–732 P1
Biotin‑AGGKRNDKKSKNFDT‑ 
COOH
845–859 P2
RESA‑2 Biotin‑AEKSCSRRNGEKGTVKKKK‑
COOH
317–335 P3
Biotin‑SRRNGEKGTVKKKKN‑COOH 322–336 P4
RESA‑3 Biotin‑MKNPKKA‑COOH 763–769 P5
Biotin‑LETRSKKNK‑COOH 773–781 P6
Biotin‑SEVQQDSEVD‑COOH 555–564 P Ctl
Page 4 of 13Badaut et al. Malar J  (2015) 14:278 
CB strain were amplified using 5′-GGATCCATGT-
TAGATACATCTGAAG-3′ (sense) and 5′-CTCGAGT-
TAAACATCACTAGCTGGTTC-3′ (anti-sense) as well 
as 5′-GGATCCGATGGATCTGAAGCG-3′ (sense) and 
5′-CTGCAGTTAAACATCACTAGCTGGTTC-3′ (anti-
sense) primers, respectively. The resulting PCR fragments 
were flanked by BamH1 and PstI sites, which allowed, fol-
lowing confirmation of PCR products and digestion with 
both enzymes, cloning in frame into the corresponding 
restriction sites of the pMal-c4X polylinker.
rRESA-1B and rRESA-3B maltose-binding fusion 
proteins were overexpressed in XL10 Gold ultracom-
petent cells (Agilent). Overnight cultures were diluted 
1/100 in Luria broth (LB) medium containing ampicil-
lin (100  μg  ml−1) and bacteria were grown until the 
A600 reached ~0.5. Induction of MBP fusion proteins 
was induced with Isopropyl ß-D-thiogalactoside (IPTG) 
at 0.1 mM final concentration. After 2 h at 37°C, bacte-
ria were harvested by centrifugation, and the pellet was 
resuspended cold buffer (20 mM phosphate buffer pH8, 
200  mM NaCl, 0.1% triton X100) supplemented with 
protease inhibitors (Complete EDTA free, Roche) and 
benzonase. Lysis was completed by freezing at −20°C 
overnight and thawing. Following centrifugation at 
9,000g for 30  min at 4°C, cleared supernatant was col-
lected. Soluble rRESA-1B and rRESA-3B MBP recom-
binant proteins purification was done using same buffer 
equilibrated Amylose resin column (New England Bio-
labs). rRESA-1B and rRESA-3B MBP recombinant pro-
teins were eluted using this column buffer supplemented 
with 10  mM maltose. Collected fractions (3  mL) were 
analysed by SDS-PAGE using criterion gels (4–12%). 
Figure 1 Schematic map of the location of RESA peptides and recombinant proteins on RESA protein sequences. RESA‑1 is encoded by the gene 
PFA0110w, RESA‑2 by PF11_0512 and RESA‑3 by PF11_0509. The schematic representation of the three RESA proteins (a) is detailed at the amino acid 
level for the regions containing peptides P1, P5 and P6 (b), P2 (c), P3 and P4 (d) as well as P Ctl (e). * internal stop codon
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Protein containing fractions were pooled and stored at 
−20°C.
Antibody measurements
ELISA was performed to determine plasma IgG directed 
to the two recombinant proteins and to the six peptides.
Ninety-six-well ELISA plates were coated overnight 
with 100 µL of recombinant protein solutions as well as 
MBP protein (New England BioLabs SAS, Evry, France) 
at final concentrations of 4 µg mL−1 and 0.5 µg mL−1 in 
1× phosphate buffer saline (PBS), respectively. Blocking 
buffer (1× PBS—3% milk powder—0.1% Tween 20) was 
added (150  µL per well) and plates were kept at room 
temperature for 1 h. Regarding the peptides, plates coated 
with streptavidin were incubated with 200 µL of blocking 
buffer (1× PBS—0.5% milk powder—0.1% Tween 20) at 
4°C overnight and washed three times (1× PBS—0.04% 
Tween 20). A volume of 100 µL containing each peptide 
diluted at a final concentration of 0.3  µM in 1× PBS—
0.5% milk powder—0.04% Tween 20 was incubated for 
1 h at room temperature followed by three washing steps. 
For both experiments, 100 µL of plasma samples diluted 
1:100 (recombinant proteins and MBP) and 1:200 (pep-
tides) in 1× PBS—0.5% milk powder—0.04% Tween 20 
were incubated in duplicate for 90  min at 18°C. After 
three washing steps, peroxidase-conjugated goat anti-
human IgG (Fc specific) antibody (A0170, Sigma Aldrich, 
St-Quentin-Fallavier, France) diluted 1:3,000 for recom-
binant proteins and 1:3,500 for RESA peptides, was incu-
bated for 1  h at room temperature. Bound enzyme was 
detected with 100  µL TMB (4380L, Kem-En-Tec Diag-
nostics A/S, Taastrup, Denmark), the reaction stopped 
with 30 µl of 0.25 M sulfuric acid and the optical density 
(OD) was read at 450 nm (reference filter 550 nm).
Reference positive (PC) and negative (NC) pooled con-
trol plasmas were present in each plate so as to enable 
calculation for each plate and each peptide of a normali-
zation factor for inter-plate comparisons. These normali-
zation factors were established according to the formula 
([ODm PC] − [ODm NC])/([OD PC] − [OD NC]) where 
ODm is the mean reactivity of PC or NC for all plates for 
a defined peptide and OD PC or NC is the mean reactiv-
ity of the control plasma samples for a defined peptide of 
a defined plate. The thresholds for positivity were deter-
mined from the mean OD reactivity + 2 SD of 18 plasma 
samples from non-immune individuals and were 0.741 
(MBP), 0.137 (rRESA-1B), 0.000 (rRESA-3B), 0.026 (P 
Ctl), 0.387 (P1), 0.459 (P2), 0.487 (P3), 0.482 (P4), 0.185 
(P5), and 0.352 (P6).
Cytokine assays
Plasma samples were assayed in duplicate for IFN-γ, 
TNF-α and IL-10 using ELISA assay according to the 
manufacturer’s instructions (Mabtech, Stockholm, Swe-
den). Results were expressed in pg mL−1 by reference to 
standard curves prepared in each plate with recombinant 
cytokines. Thresholds of sensitivity were 2  pg  mL−1 for 
IFN-γ, 13 pg mL−1 for TNF-α and 0.5 pg mL−1 for IL-10. 
Zero was assigned to values below the thresholds.
DNA genotyping by PCR–RFLP
Human and parasite DNA was extracted from blood 
spots as described previously [12].
Determination of the parasite resa2 T1526G mutation
The presence of the T1526G mutation was detected by 
MseI RFLP. A short resa2 gene fragment containing the 
target base was first amplified by PCR using 5′-TGATGC-
CGTAAAAGATGGTG-3′ (sense) and 5′-TCATATCTG-
CATTTATATCGACACCT-3′ (anti-sense) primers. Then 
enzymatic digestion of the PCR products by MseI (New 
England BioLabs SAS, Evry, France) left uncut those frag-
ments carrying the T1526G single nucleotide polymor-
phism [12].
Determination of the human HbS and HbC haemoglobin 
abnormalities
Carriage of HbS or HbC results from a single mutation on 
the exon 6 of the beta globin gene, located on chromosome 
11. For HbS, an A to T substitution leads to a modifica-
tion of a glutamic acid into a valine at position 6 whereas 
for HbC, a G to A substitution leads to a modification of 
a glutamic acid into a lysine at the same amino acid (aa) 
position. The same 5′-AGTCAGGGCAGAGCCATCTA-3′ 
(sense) and 5′-CAGCATCAGGAGTGGACA-3′ (anti-
sense) primers were used for the determination of both 
mutations by PCR amplification of a 369  bp product, on 
which RFLP was performed, using enzymatic digestion of 
DNA by DdeI and BseRI (Ozyme, St-Quentin-en-Yvelines, 
France) for HbS and HbC, respectively. Both mutations 
abolished the enzyme restriction sites. The amplified beta 
globin DNA subjected to DdeI cleaved into three fragments 
(201, 93 and 75 bp) when Hb normal (HbA) and into two 
fragments (294 and 75 bp) when HbS. When subjected to 
BseRI, it cleaved into two fragments (259 and 110 bp) when 
Hb normal (HbA) and remained intact (369 bp) when HbC.
Statistical analysis
Effects of clinical co‑factors on severity of malaria
Clinical data collected at the time of admission and 
genetic data were compared between the SM and UM 
groups. Differences in means were tested by non-para-
metric Mann–Whitney U test or Kruskal–Wallis test (for 
more than two groups to be compared), except for age, 
where the Student’s unpaired t test was used as age was 
normally distributed.
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A multiple logistic regression was performed to test 
simultaneously the association between these factors and 
the severity of malaria. Starting with a complete model 
including all factors, a stepwise procedure with a back-
ward selection identified the most relevant predictors. 
The procedure based on the Akaike information criterion 
(AIC) was implemented in R software. Quantitative inde-
pendent variables (age, axillary temperature, fever dura-
tion, and parasitaemia) were categorized to check if they 
were linearly related to the log odds. Only age (in year) 
was found linearly related to the log of odds and was 
included as quantitative variable in the model. The three 
others were considered as categorical: three categories 
were defined for duration of fever (1–2, 3–4 and ≥5 days) 
and axillary temperature (<38, 38–39.5 and ≥39.5°C); 
parasitaemia were divided in quartiles.
Analysis of the anti‑RESA antibody response
The relationships between immune responses to RESA 
and the severity of malaria were explored in two differ-
ent ways. First, a non-hierarchical cluster analysis was 
performed to identify groups of children with similar 
immune responses, and study the relation between these 
groups and the risk of severe malaria. Second, the same 
approach as for clinical factors was used through a mul-
tiple logistic regression with a backward selection to 
identify the set of antibody responses associated with the 
severity of malaria.
Children were grouped into distinct clusters on the 
basis of their similarities of immune responses to RESA 
peptides and recombinant proteins independently of 
their clinical status. The k-means method implemented 
in Cluster 3.0 software [45] was used to partition children 
on the basis of their qualitative responses (responder or 
non-responder) to the eight antigens. K-means algorithm 
aimed to find the best partition of n entities in k clus-
ters (where k is user-defined) so that the total distance 
between the group members and its centroid is mini-
mized [46]. Each child was defined by an 8-dimensional 
vector of binary data (one dimension for each antigen). 
The similarities between children were measured by the 
Euclidean which is defined as:
where xi and yi represent the response values for chil-
dren x and y respectively against antigen i, and n is the 
total number of antigens considered. K-means cluster 
analysis was successively performed for different num-
bers of groups (k = 3, 4 and 5). As partition obtained by 
this method depends on initial random assignment, for a 
given k, 2,000 iterations of K-means clustering algorithm 
d
(
x, y
)
=
1
n
n∑
i=1
(
xi − yi
)2
were run to ensure to get the optimal clustering solu-
tion. At the end the best partition was chosen consider-
ing the number of times the optimal solution was found 
among the 2,000 iterations and examining the different 
partitions of children. For partitions with k > 3, k-means 
algorithm identified small groups of children with less 
than ten individuals, thus a three-group partition was 
retained. Visualization of results was done using Java 
TreeView software [47]. The relation between the clusters 
and clinical status was tested including the groups in a 
multiple logistic regression adjusted on factors that will 
be found associated with the severity of malaria.
In the second analysis, a multiple logistic regression 
was performed with a backward procedure. The initial 
model included all the antibody responses (considered as 
binary variables) and clinical factors associated with SM.
Analysis of the cytokine patterns
Pearson correlation was calculated between quantitative 
antibody responses and cytokine production. Mann–
Whitney U test or Kruskal–Wallis test were used to 
compare cytokine production between the SM and UM 
groups, groups defined by genetic defects (resa2 T1526G 
mutation, HbS, HbC) and immunological groups.
For all analyses, due to the large number of statistical 
tests performed, P values less than 0.01 were considered 
significant.
Results
Clinical characteristics of the children
The severe malaria group consisted of 47 children with 
severe malarial anaemia only, one child with cerebral 
malaria only, and six children with both severe anaemia 
and cerebral malaria.
Table 2 summarizes the main characteristics of the SM 
and UM groups of children. The sex ratios of the SM and 
UM groups did not differ (P = 0.63). UM children were 
older than SM ones (P < 0.0001). At admission, UM chil-
dren were more febrile than SM children (P = 0.01) but 
their fever tended to last for a shorter time (P =  0.07). 
Patients of the SM group had a trend for higher parasite 
density than patients of the UM group (P =  0.06). The 
prevalence rate of abnormal haemoglobins was 19.6%, 
distributing equally between the carriage of HbS (9.8%) 
and HbC (9.8%), mostly at the heterozygous state. Only 
one HbSS and one HbCC children were recorded, in the 
SM and the UM groups, respectively. There was no HbSC 
carrier. The clinical presentation of malaria was not 
affected by the type of haemoglobin or by the presence of 
the T1526G mutation in the resa2 gene.
When clinical (age, temperature, fever duration, and 
parasitaemia) and genetic (haemoglobin genotypes, 
resa2 T1526G alleles) factors were considered in a 
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multiple logistic regression, the final model defined by 
the backward procedure included the four clinical factors 
(Table 3). In this model, risk of severe malaria decreased 
linearly with age (odds ratio (OR) [95% confidence inter-
val (CI)]  =  0.35 [0.17; 0.58], P  =  2.7  ×  10−4) whereas 
parasitaemia values distributed in the upper quartile 
[OR (95% CI) = 6.70 (1.30; 54.90), P = 0.04] favoured the 
occurrence of severe malaria. Both axillary temperature 
at enrolment and fever duration were kept in the model 
even if associations were not significant (global P = 0.06 
and 0.13, respectively). The fever duration (3–4  days 
compared to 1–2  days) was weakly associated with a 
higher risk of SM [OR (95% CI)  =  5.71 (1.01; 42.95), 
P  =  0.06] and a high axillary temperature (≥39.5°C) 
appeared indicative of an UM [OR (95% CI) = 0.12 (0.01; 
0.98), P  =  0.06]. No impact of haemoglobin genotypes 
or resa2 mutation was recorded at this final stage of the 
analysis. In the following analyses, association between 
anti-RESA antibody responses and severe malaria were 
adjusted on age, parasitaemia and fever duration. As axil-
lary temperature could not be considered itself as a pre-
dictor of severity of malaria infection it was not included 
in models in order to avoid over fitting.
Anti‑RESA antibody responses in relation to clinical malaria
Validation by the measured IgG of the design of recombinant 
proteins and peptides
ELISA performed with a rRESA protein can detect 
not only antibodies raised against this protein but also 
against the other RESA proteins. The ELISA assay for the 
measurement of anti-rRESA IgG was validated by the fact 
that sera recognized and cross-reacted with both rRESA-
1B and rRESA-3B (Spearman rank correlation, ρ = 0.451; 
P = 0.0002) while the same sera did not cross-react with 
the MBP control protein (for rRESA-1B : ρ  =  0.162; 
P = 0.13 and for rRESA-3B : ρ = 0.023; P = 0.13).
Because the hypothetic B cell epitopes were chosen in 
non-homologous parts of each RESA protein, the meas-
urement of anti-peptide antibodies was RESA protein-
specific. Similarly, a validation of the ELISA assay for the 
Table 2 Characteristics of 102 children with severe (SM) or uncomplicated (UM) malaria
a 1 missing value.
b 16 missing values.
c P value of the Chi-Square test.
d P value of the Student’s unpaired-t test.
e P value of the Mann–Whitney U test.
SM (n = 54) UM (n = 48) P
Sex ratio (M/F) 1.7 (34/20) 1.4 (28/20) 0.63c
Age (years): mean (±SD) 2.9 (±1.7) 7.1 (±3.8) <0.0001d
Fever duration (days): median (interquartile range IQ25–75)a 4 (3–5) 3 (2–5) 0.07e
Axillary temperature (°C): mean ± SDb 38.4 (±0.8) 38.9 (±1.0) 0.01d
Parasitaemia (%): median (interquartile range IQ25–75) 4.3 (1.1–13.0) 3.0 (1.0–6.0) 0.06e
Haemoglobin genotype (n)
 HbAA 46 36 0.41c
 HbAS or HbSS 4 6
 HbAC or HbCC 4 6
resa2 T1526G allele (n)
 W 43 43 0.19c
 WM 3 3
 M 8 2
Table 3 Clinical factors associated with severe malaria
a Information on axillary temperature was available for 86 children.
b Presented is the final logistic regression model obtained by a stepwise 
procedure based on AIC criterion.
Parameters Na Odds ratio (95% CI) Pb
Age (years) 86 0.35 (0.17; 0.58) 2.7 × 10−4
Fever duration (days)
 1–2 18 1 0.13
 3–4 41 5.71 (1.01; 42.95)
 ≥5 27 2.69 (0.40; 21.93)
Parasitaemia (quartiles)
 Q1–Q3 (<8%) 71 1 0.04
 Q4 (≥8%) 15 6.70 (1.30; 54.90)
Axillary temperature
 <38°C 23 1 0.06
 38–39.5°C 44 1.03 (0.22; 4.47)
 ≥39.5°C 19 0.12 (0.01; 0.98)
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measurement of anti-peptide IgG was brought by the 
absence of recognition by sera of the non-epitopic pep-
tide P Ctl, as well as by high variability in the sera rec-
ognition of distinct peptides. Plasma IgG directed to P1 
and P3, P1 and P4, P3 and P4 as well as P5 and P6 were 
also highly correlated, either for the whole group or for 
SM and UM groups considered separately (all ρ ≥ 0.475; 
all P ≤ 0.0005). In the same way, IgG against P2 and P4, 
P2 and P5 as well as P2 and P6 were highly correlated for 
the UM group only (all ρ ≥ 0.410; all P ≤ 0.005). No cor-
relation was observed between anti-rRESA IgG and IgG 
directed to the associated peptides.
Results from the univariate analysis
Prevalence rates of IgG responses to RESA antigens 
according to the clinical presentation of malaria are 
illustrated in Figure  2, and ranged from 35.2 to 56.3% 
for responses to RESA recombinant proteins, and from 
3.7 to 50.0% for responses to RESA peptides. The high-
est numbers of responders were recorded for rRESA-1B 
and one of its representative peptides, P2. Responders 
to P2 were more numerous among children with SM 
compared to UM (50.0 vs 22.9%, P  =  0.005) inversely 
to what was observed for P4, with 3.7% of responders 
among SM patients vs 18.8% among children with UM 
(P  =  0.01). Responders from both clinical groups had 
similar IgG levels, as presented in Table 4. Presence of 
abnormal haemoglobin (HbS or HbC) was not associ-
ated with any IgG levels to RESA proteins and peptides, 
except a trend towards lower IgG levels to P2 in HbC 
(AC or CC genotypes) carriers in comparison to HbAA 
ones [median OD (IQ25–75) = 0.6 (0.5–0.6) vs 1.0 (0.7–
1.4), P = 0.02].
Results from the multivariate analysis
The cluster analysis concluded to an optimal partition 
of children into three groups presenting particular pat-
terns of their anti-RESA antibody responses (Figure  3). 
Thirty-three children without any defined antibody 
response profile constituted the Group A. Group B 
brought together 31 responders to rRESA-1B but not to 
P2 and Group C gathered 38 responders to P2 who also 
responded in main cases to rRESA-1B. Severe malaria 
cases distributed unequally between groups, with 27 
cases (50%) in Group C, followed by 16 cases (31%) in 
Group A and 11 cases (20%) in Group B. When consider-
ing Group B as the reference group for investigating the 
cluster association with SM by a multiple logistic regres-
sion adjusted on age, fever duration and parasitaemia, 
groups were differently related to SM (global P = 0.013) 
with a greater risk for Group C [OR (95% CI)  =  7.19 
(1.85; 33.37), P  =  0.007] and a trend for Group A [OR 
(95% CI) = 4.11 (0.97; 19.76), P = 0.06].
In accordance with the results of the cluster analysis, 
the multiple logistic regression performed with a back-
ward procedure and adjusted on age, fever duration and 
parasitaemia led to a similar observation, where IgG 
response to peptide P2 tended to be related to the sever-
ity of malaria [OR (95% CI) = 4.10 (1.29; 14.81), P = 0.02] 
(Table 5).
Plasma cytokine levels in relation to clinical malaria
Plasma levels of inflammatory cytokines (IFN-γ, TNF-α 
and IL-10) were measured at enrolment in the study 
and revealed higher TNF-α levels among SM cases than 
UM ones [median content in pg ml−1 (IQ25–75) = 23.5 
(0–142.5) vs 0 (0–8.2), P = 0.004], as shown in Table 6. 
Figure 2 Prevalence rates of plasma IgG to RESA antigens in Beninese children with malaria. Bars denote the 95% confidence interval. Significant P 
values of the Chi‑Square test (P < 0.01) are indicated.
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Cytokine levels were not associated with IgG positivity 
to P2 (previously found related to the severity of malaria) 
nor to rRESA-1B and rRESA-3B, this last antigen being 
considered in the analysis for the interest placed in the 
reactivity of the immune system to it. Presence of the 
resa2 T1526G mutation was associated with IL-10 
plasma levels, the highest cytokine levels being recorded 
for children with a mixed infection compared to chil-
dren infected by parasites harbouring only wild type 
resa2 T1526G alleles [median content in pg ml−1 (IQ25–
75) = 98.3 (70.4–176.8) vs 35.2 (17.5–65.1), P = 0.004].
Discussion
The present study was intended to correlate the presence 
of immune responses against the three members of the 
Table 4 IgG levels to RESA antigens in responder children according to host and parasite characteristics
a Median values [25th–75th percentiles] expressed in OD; (number of responders).
b P value for the Mann–Whitney U test (two groups) or Kruskal–Wallis test (three groups); significant P value < 0.01.
Group rRESA‑1B rRESA‑3B P1 P2 P3 P4 P5 P6
SM 0.7 [0.3–1.7] 
(28)a
0.1 [0.1–0.7] 
(19)
0.7 [0.5–1.0] (5) 0.9 [0.6–1.42] 
(27)
0.8 [0.7–1.4] 
(5)
1.2 [1.0–1.5] 
(2)
0.4 [0.2–0.5] 
(11)
0.6 [0.5–1.0] (5)
UM 1.1 [0.4–1.9] 
(27)
0.2 [0.1–0.5] 
(23)
0.5 [0.4–0.6] 
(10)
0.8 [0.6–1.1] 
(11)
0.6 [0.5–0.6] 
(5)
0.6 [0.5–0.7] 
(9)
0.2 [0.2–0.3] 
(7)
0.9 [0.5–1.3] (7)
Pb 0.28 0.67 0.18 0.81 0.08 0.10 0.22 0.46
HbAA 0.7 [0.3–2.0] 
(43)
0.2 [0.1–0.5] 
(31)
0.5 [0.4–0.8] 
(11)
1.0 [0.7–1.4] 
(30)
0.7 [0.5–0.7] 
(8)
0.6 [0.5–0.7] 
(8)
0.2 [0.2–0.4] 
(13)
0.6 [0.4–1.1] 
(11)
HbAS or HbSS 0.7 [0.6–1.1] (9) 0.2 [0.2–0.6] (7) 0.5 [0.5–0.6] (2) 0.5 [0.5–1.0] (3) 1.8 [1.8–1.8] 
(1)
1.8 [1.8–1.8] 
(1)
0.3 [0.3–0.4] 
(4)
(0)
HbAC or HbCC 1.4 [0.8–1.8] (3) 0.5 [0.1–0.9] (4) 0.4 [0.4–0.5] (2) 0.6 [0.5–0.6] (5) 0.6 [0.6–0.6] 
(1)
0.7 [0.6–0.7] 
(2)
0.3 [0.3–0.3] 
(1)
0.9 [0.9–0.9] (1)
P 0.61 0.49 0.24 0.02 0.43 0.22 0.66 0.88
resa2  
T1526G allele
0.9 [0.4–2.3] (8) 0.3 [0.1–0.4] (8) 0.4 [0.4–0.4] (3) 0.9 [0.7–1.3] (7) 0.6 [0.6–1.0] 
(3)
0.5 [0.5–0.5] 
(1)
0.3 [0.3–0.4] 
(2)
0.4 [0.4–0.4] (2)
no resa2 
T1526G allele
0.7 [0.3–1.7] 
(47)
0.2 [0.1–0.8] 
(34)
0.6 [0.5–0.8] 
(12)
0.8 [0.6–1.4] 
(31)
0.7 [0.6–0.8] 
(7)
0.7 [0.5–0.7] 
(10)
0.3 [0.2–0.4] 
(16)
1.0 [0.6–1.1] 
(10)
P 0.45 0.90 0.04 0.95 0.91 0.53 0.57 0.08
Figure 3 Graphical representation of anti‑RESA antibody profiles in three groups obtained by non‑hierarchical cluster analysis. Each row represents 
the children’s responses to one antigen: P1 to P6 synthetic peptides; rRESA‑1B and rRESA‑3B recombinant proteins. In columns are pictures of the 
responses against the different antigens for one child. Thus each rectangle at the intersection between rows and columns represents the response 
against one antigen for one child. A dark grey box represents a positive response and a light grey box a negative one.
Table 5 Association between  IgG responses and  malaria 
severity
a Number of responders.
b Each antibody response was tested for association with severe malaria in a 
multiple logistic regression adjusted on age, fever duration and parasitaemia; 
significant P value < 0.01.
Antigens Na Odds ratio (95% CI) Pb
P1 15 0.41 (0.08; 1.95) 0.27
P2 38 4.10 (1.29; 14.81) 0.02
P3 10 1.08 (0.16; 8.59) 0.94
P4 11 0.31 (0.03; 2.16) 0.26
P5 18 0.85 (0.16; 4.59) 0.85
P6 12 0.42 (0.05; 4.0) 0.41
rRESA‑1B 55 0.43 (0.12; 1.37) 0.16
rRESA‑3B 42 0.86 (0.27; 2.78) 0.80
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RESA protein family with the severity of malaria attacks. 
For this purpose, recombinant proteins were engineered 
for the two repetitive RESA-1 and RESA-3 proteins and 
peptides representing putative B epitopes of each RESA 
protein were designed and synthesized. In most previous 
studies performed on the RESA antigen, peptides were 
representative of central or C-terminal repetitive RESA-1 
sequences [20, 21, 24]. Instead, in the present study, pep-
tides were chosen outside these repetitive blocks in zones 
of non-homology of the three proteins or correspond-
ing to recombinant proteins reproducing the central 
and non-homologous repetitive domain of RESA-1 and 
RESA-3. No corresponding RESA-2 recombinant protein 
was included as the predicted RESA-2 protein is devoid 
of such repetitive sequences. These peptides were dem-
onstrated to be the targets of specific antibodies as illus-
trated by prevalence rates ranging from 3.7 to 50%, which 
matched anti-peptide antibody prevalence rates reported 
in previous studies using RESA peptides reproduc-
ing parts of the repetitive blocks [25, 27]. Peptides were 
designed to prevent antibody cross-reactivity within the 
RESA family.
No correlation was observed between the IgG recogni-
tion of rRESAs and synthetic peptides. Since RESA pro-
teins have highly homologous sequences, they should 
induce cross-reacting antibodies. Thus, the observed 
IgG reactivity to a defined RESA protein results from a 
contribution of the IgG responses directed to identical 
sequences in RESA-1, RESA-2 and RESA-3, but does not 
reflect the immunogenicity of a defined protein. Moreo-
ver, because no RESA three-dimensional structure has 
been solved, all designed peptides may not have been 
optimized for their antigenicity and for being fully acces-
sible to the humoral immune system. A single peptide 
can by no means recapitulate the complete antigenic 
properties of a full-length protein. Nevertheless, the 
serum recognition of a pertinent peptide allows esti-
mating the ability of a protein to induce antibodies dur-
ing the Plasmodium life cycle and therefore to relate its 
presence on the red blood cell surface to the different 
clinical presentations of malaria. Globally, the antibody 
responses reported in this study reinforced the inter-
est in the already known immunogenicity of the RESA-1 
antigen, as no relation to malaria severity was put for-
ward for antibody responses directed to RESA-2 peptides 
and RESA-3 peptides or RESA-3 recombinant protein. 
Indeed, only the anti-P2 IgG response was related to 
malaria severity. This observation was further supported 
by a cluster analysis, which allowed distributing children 
into three groups with distinct profiles of their anti-RESA 
antibody responses: the group of children responders to 
P2 and inconsistently responders to rRESA-1B presented 
an association with malaria severity. This association 
was independent of age, fever duration and parasitaemia 
levels.
It was previously shown among the same population 
group that the T1526G resa2 gene mutation was associ-
ated with parasitaemia >4%, leading to hypothesize that 
the restoration of a full-length RESA-2 protein could 
Table 6 Plasma cytokine levels at  enrolment of  Beninese 
children, in relation to host and parasite characteristics
a Median values (25th–75th percentiles) expressed in pg/ml−1, whole 
population group considered.
b P value for the Mann–Whitney U test (two groups) or Kruskal–Wallis test (three 
groups); significant P value < 0.01.
Group (n) IFN‑γ TNF‑α IL‑10
Clinical groups
 SM (54) 10.4 (3.1–30.9)a 23.5 (0.0–142.5) 34.2 (16.0–66.9)
 UM (48) 5.3 (0.0–39.5) 0.0 (0.0–8.2) 45.9 (24.9–78.0)
 Pb 0.37 0.004 0.28
Antibody responder groups
 Group A (33) 8.3 (2.1–31.3) 0.0 (0.0–88.3) 36.5 (23.7–90.0)
 Group B (31) 5.2 (2.1–27.5) 0.0 (0.0–125.4) 43.7 (15.4–64.6)
 Group C (38) 10.3 (3.1–33.0) 0.0 (0.0–92.5) 34.2 (14.1–64.3)
 P 0.70 0.98 0.64
 P2—positive 
response (38)
10.3 (3.1–33.0) 0.0 (0.0–92.5) 34.2 (14.1–64.3)
 P2—negative 
response (64)
6.0 (2.0–31.3) 0.0 (0.0–90.2) 42.2 (19.5–78.0)
 P 0.42 0.99 0.66
 rRESA‑1B—posi‑
tive response 
(55)
9.9 (3.0–35.1) 0.0 (0.0–109.9) 42.7 (16.9–64.2)
 rRESA‑1B—neg‑
ative response 
(47)
7.4 (2.0–19.6) 0.0 (0.0–69.6) 34.9 (18.7–87.0)
 P 0.20 0.72 0.99
 rRESA‑3B—posi‑
tive response 
(42)
5.0 (2.0–27.8) 0.0 (0.0 37.9) 39.1 (15.4–63.8)
 rRESA‑3B—neg‑
ative response 
(60)
9.8 (3.0–36.9) 0.0 (0.0–134.1) 38.7 (19.4–72.0)
 P 0.12 0.09 0.75
 HbAA (82) 9.1 (2.4–30.9) 0.0 (0.0–85.1) 41.4 (18.0–79.4)
 HbAS or HbSS 
(10)
12.6 (2.2–36.1) 0.0 (0.0–503.4) 37.2 (16.4–56.8)
 HbAC or HbCC 
(10)
6.5 (2.7–29.8) 0.0 (0.0–60.9) 35.7 (19.1–52.8)
 P 0.99 0.42 0.69
 resa2 T1526G 
allele W (86)
9.1 (2.2–29.8) 0.0 (0.00–68.41) 35.2 (17.5–65.1)
 resa2 T1526G 
allele WM (6)
37.3 (2.7–86.4) 46.0 (15.2–200.3) 98.3 (70.4–176.8)
 resa2 T1526G 
allele M (10)
9.6 (2.5–34.5) 32.0 (0.0–116.4) 24.7 (12.2–83.5)
 P 0.68 0.34 0.02
Page 11 of 13Badaut et al. Malar J  (2015) 14:278 
contribute with the other members of the RESA protein 
family to remodelling the erythrocyte membrane [12] and 
therefore to favouring high parasite densities which are 
often associated with the severity of the infection [48]. In 
this state of mind, it makes sense that high plasma IL-10 
levels were preferentially found among patients present-
ing T1526G mutant parasites. Indeed, IL-10 plays a dual 
role in malaria pathology: it may be beneficial by reduc-
ing the inflammatory response, such as that induced by 
TNF-α, the plasma levels of which were higher in SM 
compared to UM children, in agreement with numerous 
studies [29–31]; however, IL-10 may also be detrimen-
tal by decreasing the cellular immune responses which 
are helpful for parasite control by the host [29]. A subtle 
imbalance between pro- and anti-inflammatory cytokines 
determines the course of malaria pathology, and the fact 
that high TNF-α plasma levels among SM children were 
not counterbalanced by high IL-10 plasma levels suggests 
that in SM children at admission, IL-10 had not yet ful-
filled its immuno-regulatory role by down regulating the 
TNF-α inflammatory response [49].
In link with an explanation towards IL-10 as a marker 
of severity was the observation in the present study of the 
highest IL-10 plasma levels among children infected by 
mixed isolates presenting wild and mutant resa2 alleles. 
This observation was based on only six samples but still 
suggests the following hypotheses. Even if the multiplic-
ity of infection (MOI) was not evaluated in this study by 
genotyping polymorphic parasite genes such as msp1 or 
msp2, the presence of concomitant wild and mutant resa2 
T1526G alleles was indicative of polyclonality. There 
seems to be a consensus that high MOI are found during 
symptomatic malaria episodes of young children from 
endemic areas, who have a low level of acquired immu-
nity [50]. A study among children in Uganda reported 
a higher MOI in severe than in uncomplicated malaria 
[51]. As no association was found in the present study 
between anti-P3 and anti-P4 IgG, specific of reactivity 
to RESA-2, and the clinical presentation of malaria, it is 
not possible to firmly establish whether the restoration 
of a full-length RESA-2 protein, thanks to the T1526G 
mutation, may contribute to malaria severity. Such an 
assessment could be made possible if synthetic peptides, 
specific of the restored portion of RESA-2, could be 
designed. Moreover, the above comments would benefit 
from being strengthened by results of a kinetic study of 
both cytokine plasma levels and circulating blood para-
site clones, which fluctuations cannot be detected by a 
cross-sectional study.
Conclusion
To better understand malaria pathogenesis, the role 
of P.  falciparum proteins exported to the erythrocyte 
membrane in order to help the infected erythrocyte to 
escape elimination by the spleen, must be deciphered. It 
is the case of the three components of the RESA protein 
family, whose respective roles in increasing red blood cell 
resistance to febrile conditions are difficult to distinguish 
due to great sequence homologies. This study offered the 
first opportunity to dissect the antibody recognition of 
each RESA protein using synthetic peptides representing 
specific sequences of each RESA protein. The measure-
ment of naturally acquired IgG in the context of clinical 
malaria indicated a possible relationship to severe malaria 
of anti-RESA-1, but not anti-RESA-2 nor anti-RESA-3 
IgG. As the design of the study was transversal, the pro-
tective role of these IgG cannot be ascertained. Increased 
IL-10 plasma levels in children harbouring multiclonal 
P. falciparum infections on the basis of the T1526G resa2 
gene polymorphism may be suggestive of a pathogenic 
role of the full-length restored RESA-2 protein. Never-
theless, the small sample size in this study implies the 
same observations to be made in an independent study 
or a larger sample in order to be confirmed. At term, the 
deepening of the understanding of the malaria pathogen-
esis will provide new possibilities for interventions aimed 
at reducing parasite survival in the human host.
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